Defactinib induces dissociation of PI3K from FAK in esophageal squamous cell carcinoma, thus resulting in impaired AKT signaling and in the transcriptional downregulation of several oncogenes such as SOX2, MYC, EGFR, MET, MDM2 and TGFBR2, thus reducing tumor growth and metastatic ability [76]. Here, MDM2 is linked to neoplasm.